Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transarterial chemoembolization Clear all
Terminated Phase 3 Interventional Results available

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

NCT02762266
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
Interventions
Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol
Radiation · Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 2, 2026, 11:50 AM EDT
Recruiting Phase 1 Interventional

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE), Lenvatinib
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead

NCT01259024
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
transarterial chemoembolization using a drug-eluting bead
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 2, 2026, 11:50 AM EDT
Active, not recruiting Phase 2 Interventional

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT04728633
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Interventions
Carmustine, Ethiodized Oil, Transarterial Chemoembolization, Medical Device Usage and Evaluation
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma

NCT00844883
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatoma
Interventions
sorafenib, LC Bead-TACE
Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 2, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib in combination with pembrolizumab, Loco-regional therapy
Drug · Procedure
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00335829
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, chemotherapy, embolization therapy, hepatic artery infusion
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 2, 2026, 11:50 AM EDT
Active, not recruiting Phase 2 Interventional

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

NCT03937830
View directory record Official record
Conditions
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Recruiting Phase 2 Interventional

Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

NCT06261814
View directory record Official record
Conditions
Liver Neoplasms
Interventions
Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization, Medical Chart Review
Drug · Procedure · Other
Lead sponsor
john eisenbrey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Active, not recruiting Not applicable Interventional

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

NCT05537402
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Terminated Not applicable Interventional Results available

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

NCT02147301
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization
Interventions
LC Bead
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

NCT02471313
View directory record Official record
Conditions
Liver Cancer, Liver Neoplasm, Hepatocellular Carcinoma, HCC
Interventions
[18F] FMISO
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

NCT02753881
View directory record Official record
Conditions
Liver Cancer
Interventions
whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 2, 2026, 11:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

NCT05842174
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Hydroxychloroquine, Lipiodol, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Not listed Phase 1 Interventional

TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

NCT01721941
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Phase I dose level 1, Phase I Dose level 2, Phase I Dose level 3
Drug
Lead sponsor
Scripps Clinic Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 2, 2026, 11:50 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

NCT02997956
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tocilizumab, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 2, 2026, 11:50 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT04472767
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Transarterial Chemoembolization
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

NCT00857805
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Transarterial Chemoembolization, Proton Beam Radiotherapy
Procedure · Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 2, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

NCT05776875
View directory record Official record
Conditions
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Interventions
Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
Drug · Combination Product
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
Drug · Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 2, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NCT00539253
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
gadobenate dimeglumine (MultiHance)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 2, 2026, 11:50 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 2, 2026, 11:50 AM EDT